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Abstract. The parvins are a family of proteins involved 
in linking integrins and associated proteins with intracel-
lular pathways that regulate actin cytoskeletal dynamics 
and cell survival. Both a-parvin (PARVA) and b-parvin 
(PARVB) localize to focal adhesions and function in 
cell adhesion, spreading, motility and survival through 
interactions with partners, such as integrin-linked kinase 
(ILK), paxillin, a-actinin and testicular kinase 1. A com-
plex of PARVA with ILK and the LIM protein PINCH-1 
is critical for cell survival in a variety of cells, includ-
ing certain cancer cells, kidney podocytes and cardiac 
myocytes. While PARVA inhibits the activities of Rac1 
and testicular kinase 1 and cell spreading, PARVB binds 
aPIX and a-actinin, and can promote cell spreading. In 
contrast to PARVA, PARVB inhibits ILK activity and 
reverses some of its oncogenic effects in cancer cells. 
This review focuses on the structure and function of the 
parvins and some possible roles in human diseases.
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Introduction
The actin cytoskeleton plays a critical role in maintaining 
cellular shape, regulating cell motility and responding to 
mechanical strain. It is highly dynamic and responds to 
extracellular stimuli, such as hormones and growth fac-
tors, cell-cell adhesion and variations in the extracellular 
matrix (ECM). Cell-ECM adhesion is mediated primarily 
by integrins and associated proteins. Integrins function 
as transmembrane receptors for ECM proteins such as 
fibronectin, laminin and collagen. Through protein com-
plexes associated with their cytoplasmic domain, such 
as those containing talin, integrin-linked kinase (ILK), 
PINCH, parvin, paxillin and/or focal adhesion kinase 
(FAK), integrins transduce bi-directional signals between 
the ECM and intracellular signaling pathways. Integrin-
associated proteins can integrate cell adhesion-mediated 
signaling with other extracellular signals, such as those 
originating from growth factor receptors, through a va-
riety of intracellular signaling pathways. In addition to 
regulating cell survival, proliferation and gene expres-
sion, integrin-mediated signaling often results in changes 
in the actin cytoskeleton leading to cell shape change and 
motility. In this article, we will review current knowl-
edge about a family of proteins, the parvins, which play 
a critical role in transducing signals from integrins to the 
actin cytoskeleton and intracellular signaling proteins.
Structural features
The mammalian parvin protein family has three members 
(a-, b- and g-parvin). They were identified independently 
at approximately the same time by several laboratories 
based on their protein binding activities or sequence ho-
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mology. Approximately 5 years ago, Nikolopoulos and 
Turner [1] identified and cloned a new F-actin and paxil-
lin LD1 motif binding protein from a rat complementary 
DNA (cDNA) library and named it actopaxin. In a yeast 
two-hybrid screening of ILK binding partners, Tu et al. 
[2] identified and cloned a new ILK binding protein that 
contains two CH domains and hence named it Calponin 
Homology domain-containing ILK Binding Protein or 
CH-ILKBP. In an independent yeast two hybrid screen-
ing, Yamaji et al. [3] identified and cloned another new 
protein that interacts with ILK, which they named affix-
in. Based on sequence homology with the actin binding 
domain of a-actinin, Olski et al. [4] identified and cloned 
three structurally related proteins and named them a-, b- 
and g-parvin, respectively. A comparison of the DNA and 
protein sequences shows that actopaxin and CH-ILKBP 
are identical to the alpha member and affixin is identical 
to the beta member of the parvin family. The members 
of the parvin family are encoded by three different genes 
(parva, parvb and parvg) in mammalian organisms. 
Proteins that are structurally and functionally related 
to parvins have been identified in invertebrates such as 
Caenorhabditis elegans by sequence analyses [4] and 
independent genetic studies [5]. Thus, Parvin appears to 
be an ancient protein family and is well conserved during 
evolution. 
Human PARVA, PARVB and PARVG contain 372, 364 
and 331 amino acids (with theoretical molecular masses 
of 42,330, 41,770 and 37,485), respectively (fig. 1). In 
addition, PARVB transcript has two alternative initiation 
sites, which result in proteins of 350 and 313 amino acids 
(with theoretical molecular masses of 40,130 and 35,924). 
The shorter forms of PARVB are herein respectively ab-
breviated as PARVB-s and PARVB-ss in contrast with 
full-length PARVB-l (fig. 1). In human rhabdomyosar-
coma cells, an additional alternatively spliced isoform of 
PARVB was identified, named CLINT [6]. This isoform 
originates from an alternative upstream exon coding for 
70 amino acids and results in a protein with 397 amino 
acids (fig. 1). For a comprehensive study of the genomic 
organization of the parvins see [7].
Human PARVA and PARVB share 74% identity and 85% 
similarity, whereas the more distantly related PARVG 
shares 42% identity and 67% similarity with PARVA. 
The most distinct feature of parvins is the presence of 
two calponin homology (CH) domains in their C-ter-
minal regions, named CH1 and CH2 (fig. 1). Each CH 
domain comprises approximately 100 amino acids, sepa-
rated by a 60-amino acid linker. These CH domains are 
considered ‘atypical’ in that they do not exactly match 
the consensus sequences of type 1 and type 2 CH do-
mains present in a large number of actin binding proteins 
such as a-actinin, spectrin and filamin [4, 8]. The parvin 
CH1 domain is more related to the type 1 CH domain of 
spectrin, whereas the second CH domain is more related 
to the type 1 CH domain of a-actinin [4, 8]. The CH1 
and CH2 domains of the parvins are tentatively classified 
as type 4 and type 5 CH domains, respectively [8]. In 
addition to the conserved CH domains, the parvins have 
a 60-amino acid linker with some homology to regions 
Figure 1. Structural features 
of PARVA and PARVB 
proteins. Numbers indicate 
amino acid positions. Protein 
binding sites are indicated 
with a horizontal line. Effect 
of point mutations is indicated 
by ↓. Sequences required for 
localization are indicated by 
↑. Both PARVA and PARVB 
contain two calponin homol-
ogy domains (CH) and nu-
clear localization sequences 
(NLS) at their N-termini. In 
addition to full-length PARVB 
(PARVB-l), PARVB-s and 
PARVB-ss can be produced 
by alternative translation 
initiation. A PARVB isoform 
expressed from alternative 5’ 
exons (CLINT) has also been 
detected in certain cell types.
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preceding the CH1 of b-spectrin and plectin, as well as 
N-terminal extensions that show a high degree of vari-
ability between the various parvins, from 82 amino acids 
in PARVG to 125 amino acids in PARVB and 133 amino 
acids in PARVA (fig. 1). Both PARVA and PARVB have 
nuclear localization signals in the N-terminal extensions, 
as well as src-homology SH3 binding sites of the consen-
sus PXXP, where X is any amino acid but cysteine [4].
Tissue distribution
In mammalian organisms, PARVA and PARVB are 
ubiquitously expressed but enriched in heart and skeletal 
muscle (table 1). In the spleen and platelets [9], the pre-
dominant isoform of PARVB is a short form translated 
from a downstream initiation codon, PARVB-ss (fig. 1). 
PARVG has a more restricted tissue distribution, as de-
termined from messenger RNA (mRNA) blots, with pre-
dominance of lymphoid and hematopoietic tissues [7]. 
Since currently there are no published studies addressing 
the functions of PARVG, we will focus on PARVA and 
PARVB in our discussions. 
Parvin interactions
Parvin proteins do not possess intrinsic catalytic activities 
and therefore their functions are mediated through in-
teractions with various binding partners. One of the key 
parvin binding partners is ILK [10–13] (fig. 2). PARVA 
and PARVB have clearly been demonstrated to interact 
with ILK by different binding assays including yeast 
two-hybrid, co-immunoprecipitation and glutathione S-
transferase (GST) fusion pull-down assays [2, 3, 14]. The 
ILK binding site has been mapped to the CH2 domain of 
PARVA and PARVB. F271 within this domain appears to 
be critical for the ILK binding activity of PARVA, as a 
single point mutation at this position (F271D) abolished 
its interaction with ILK [2]. Although the CH2 domain is 
sufficient for interacting with ILK, residues located out-
side of the CH2 domain can modulate the interaction with 
ILK. The N-terminus of PARVA contains multiple pro-
line-directed Ser/Thr phosphorylation sites [15]. Deletion 
Table 1. Relative tissue distribution of parvin proteins. An arbitrary 
scale of + to +++ refers to the relative intensity of the bands in 
Western blot analysis [2–4, 34]. (+ to +++); protein expression not 
determined, inferred from mRNA expression [4, 7]. ?; expression 
unknown. The expression levels were based on results from differ-
ent experiments and therefore might not always be directly compa-
rable (see [2–4, 7, 34] for detail). 
Tissue PARVA PARVB PARVG
Heart +++ ++ (+ to ++)
Skeletal Muscle ++ +++ (+)
Brain + + (+)
Lung + to ++ + (++)
Liver ++ + (+ to ++)
Pancreas (++) ? ?
Intestine ++ + (++)
Thymus + + (+++)
Spleen + +++ (PARVB-ss) (+++)
Testis + + (+++)
Kidney ++ (++) (+)
Placenta ++ (+) (+)
Figure 2. A working model 
for the functions of parvins 
and their binding proteins. 
ILK binds PINCH through its 
N-terminal domain and binds 
PARVA or PARVB through its 
C-terminal domain, resulting 
in formation of PINCH-ILK-
parvin ternary complexes. 
Formation of these complexes 
occurs before localization to 
integrin-rich adhesion sites 
and is required for preventing 
degradation of ILK, PINCH1 
and parvins. Recruitment of 
these complexes to integrin-
rich adhesion sites is mediated 
by interactions of the complexes with additional proteins, such as b1-integrin, Mig-2 and paxillin. Phosphorylation of the N-terminus of 
PARVA increases binding to ILK and inhibits binding to TESK-1. Since PARVA inhibits TESK-1 activity, release of TESK-1 upon phos-
phorylation of PARVA results in inhibition of cofilin by phosphorylation and consequently, reduction of the turnover rates of actin filaments. 
PARVA can bind to F-actin in vitro but the functional significance of this interaction remains to be established. The PINCH1-ILK-PARVA 
complex plays a critical role in cell survival by promoting membrane recruitment of Akt and its activation by phosphorylation. PARVA and 
PARVB compete for binding to ILK and have opposite effects on ILK kinase activity. While PARVA binding increases ILK kinase activity, 
PARVB binding represses it. Also, PARVB promotes adhesion and spreading through binding of a-actinin, a-PIX and activation of Rac1, 
while PARVA represses Rac1.
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of 22 residues from the N-terminus of PARVA inhibits the 
proline-directed Ser/Thr phosphorylation of PARVA and 
reduces its complex formation with ILK [16].
On the other side of the binding interface, the parvin bind-
ing site has been mapped to the C-terminal kinase domain 
of ILK [2, 14]. The binding of PARVA and PARVB to 
ILK is mutually exclusive [17], suggesting that a single 
CH2-binding site in the ILK C-terminal domain mediates 
the interactions with PARVA and PARVB. ILK contains 
a PH-like motif that partially overlaps with the C-termi-
nal kinase domain. The PH-like motif can interact with 
certain phospholipids such as PIP3, which is produced by 
the action of PI3-kinase. The PI3-kinase signaling path-
way appears important for regulation of the ILK-PARVA 
interaction, since PI3-kinase inhibition or overexpression 
of the PIP3 phosphatase PTEN can reduce the interaction 
[18]. However, deletion of amino acid residues 180–190 
within the PH-like motif does not inhibit the PARVA 
interaction [19]. 
In addition to binding PARVA or PARVB through the 
C-terminal domain, ILK interacts with PINCH-1 and 
PINCH-2, members of a family of focal adhesion pro-
teins that consist of five LIM domains, through the N-
terminal ankyrin repeat domain of ILK [19–21]. Through 
these interactions, PINCH, ILK and parvin proteins form 
ternary complexes in cells (fig. 2). The formation of 
the PINCH-ILK-parvin complexes occurs prior to their 
localization to cell-matrix adhesions [19]. One impor-
tant consequence of the formation of the PINCH-ILK-
parvin complexes is the stabilization of these proteins 
by protecting them from proteosomal degradation [22]. 
Furthermore, formation of the PINCH-ILK-parvin com-
plexes facilitates their localization to cell-matrix adhe-
sions. Interestingly, treatment of cells with calphostin C 
dramatically inhibits the formation of the PINCH-ILK-
parvin complexes [19], suggesting a role of protein ki-
nase C (PKC) or other calphostin C-responsive signaling 
pathways in this process.
Another interaction mediated by PARVA is that with 
paxillin, an important component of focal adhesions [23, 
24]. Nikolopoulos et al. have mapped the paxillin binding 
site to amino acids 273–290 of PARVA and the PARVA 
binding sites to LD1 and LD4 motifs of paxillin [1, 14]. 
Interestingly, paxillin also interacts with ILK through the 
LD1 motif [14]. The interactions of paxillin with ILK 
and PARVA likely contribute to the localization of the 
PINCH-ILK-parvin complexes to focal adhesions.
In addition to interacting with ILK and paxillin, PARVA 
can interact with F-actin [1, 4]. PARVA binds to F-ac-
tin with an affinity that is comparable to those of many 
other actin binding proteins (Kd = 8.4 µM) [4]. Detailed 
characterization of the F-actin binding sites in the CH 
domains of PARVA remains to be done. 
Recently, Lalonde et al. [25] showed that PARVA binds 
to testicular protein kinase 1 (TESK1). TESK1 can phos-
phorylate cofilin and promote F-actin polymerization and 
cell spreading [26–28]. Interestingly, PARVA binds to 
TESK1 and inhibits its activity [25]. RNA interference 
(RNAi)-mediated depletion of PARVA promotes cell 
spreading [17]. PARVA likely suppresses cell spread-
ing by regulating multiple signaling pathways, including 
suppression of Rac1 activation [17] and inhibition of 
TESK1 [25].
As mentioned above, PARVB, like PARVA, interacts 
with ILK. However, despite the structural similarity and 
extensive efforts, PARVB has not been demonstrated to 
bind to actin or paxillin [3, 29]. Yamaji et al. [29] re-
cently demonstrated that PARVB interacts with a-actinin 
via the CH2 domain. In addition, PARVB interacts with 
aPIX [30], a guanine nucleotide exchange factor (GEF) 
for Rac1 and possibly other Rho GTPases, through its 
CH1 domain. PARVB likely functions in actin cytoskel-
etal remodeling and cell spreading via interactions with 
multiple partners, including ILK, a-actinin and aPIX.
Subcellular Localization
When cells attach to the ECM, several changes occur at 
the membrane and cytoskeleton [31, 32]. First, nascent 
cell-ECM contacts (focal complexes) are established, 
where integrins engage with the ECM and recruit pro-
teins, such as talin, paxillin, PINCH, ILK, parvins, a-ac-
tinin, vinculin, FAK and VASP. This leads to recruitment 
of additional F-actin and F-actin associated proteins and 
maturation into focal adhesions (FAs). In addition to the 
establishment of FAs, spreading cells will extend wide 
membrane protrusions, called lamellipodia, also present 
in some cells initiating directional migration. Soon after 
identification of parvins as ILK and paxillin binding 
proteins, it became apparent that protein-protein interac-
tions of parvins with these partners were critical for their 
subcellular localization. More specifically, the formation 
of complexes of ILK with parvins and the LIM proteins 
PINCH-1 and PINCH-2 became a paradigm for multi-
protein complex formation, stabilization and localization 
in the context of cell adhesion. 
Both PARVA and PARVB, together with ILK, are ob-
served in lamellipodia in spreading cells, although it 
appears that ILK, PARVB and PINCH-1 are expressed 
very early at the plasma membrane during lamellipodia 
extension before FAK, vinculin and paxillin are recruited 
[3, 20]. Established FAs clearly contain both PARVA 
and PARVB. In addition to FAs and lamellipodia, ILK, 
PINCH and PARVA staining is observed in a fibrillar 
pattern more intense towards the center of the cells [1, 4, 
19, 33]. PARVA-containing central fibers correspond to 
tensin-containing fibrillar adhesions [4]. Tensin-contain-
ing fibrillar adhesions are highly dynamic structures that 
overlay fibronectin fibrils in the ECM and move towards 
28 J. L. Sepulveda and C. Wu The parvins Cell. Mol. Life Sci.  Vol. 63, 2006 Review Article 29
the center through the action of actomyosin [31, 32]. Lo-
calization of PARVA to epithelial cell-cell adhesion junc-
tions, rich in cadherins and catenins, has been observed 
in some epithelial cells [4] but not in others [2, 34], pos-
sibly indicating some cell-type specificity. PARVB has 
been found associated with thin stress fibers (involved in 
lamellipodia protrusion), where it co-localizes with a-ac-
tinin, but is excluded from mature stress fibers (involved 
in maintaining cell architecture), where a-actinin cross-
links actin filaments [29].
The domains responsible for the various subcellular lo-
calizations of PARVA and PARVB were investigated 
by transfecting cells with various parvin mutants fused 
to green fluorescent protein (GFP). In general the GFP-
fused full-sized parvins co-localized with their endog-
enous counterparts. Using this method, localization to 
FAs and fibrillar adhesions was determined to depend 
on the CH2 domains of both PARVA [2, 4] and PARVB 
[3]. The CH2 domain alone was sufficient for FA locali-
zation, although the other regions appear to increase the 
intensity of FA localization [2, 4]. 
A single point mutation (F271D) in the CH2 domain of 
PARVA, a residue also conserved in PARVB, is sufficient 
to abolish FA localization [2]. Mutations in the putative 
paxillin binding site (PBS, amino acids 273–290 of PAR-
VA) also abolish FA localization without affecting ILK 
binding. Thus, the interaction with ILK is likely neces-
sary but not sufficient for efficient localization of PARVA 
to FAs. A mutant of ILK (F438A), which does not affect 
PARVA binding, is unable to localize to FAs, indicating 
that other interactions are also necessary for FA localiza-
tion of ILK [19]. Since this site is away from the paxillin 
binding region, it is more likely that additional proteins, 
such as Mig-2 or integrins, are also involved in recruit-
ment of the ILK-PARVA complex to the FAs. Since the 
binding between PARVA and ILK appears stronger than 
that between ILK and paxillin and the ILK-PARVA 
complex is formed even in cells without cell-matrix 
contacts [19], we favor a model whereby PINCH-1, ILK 
and PARVA form a complex prior to their localization to 
cell-matrix adhesions. The formation of the PINCH-1-
ILK-PARVA complex allows it to be recruited to FAs via 
interactions with multiple FA proteins such as integrins, 
paxillin and/or Mig-2 (fig. 2). 
Functional role of PARVA phosphorylation
As mentioned earlier, the N-terminal domain of PARVA 
contains phosphorylation consensus regions for proline-
directed serine/threonine kinase, including ERK and 
Cdc2. The Cdc2 kinase, in combination with cyclin B1, 
has been shown to phosphorylate S4, S8, S14 and S19 
of PARVA [15], and ERK can also phosphorylate the 
N-terminus of PARVA [35]. During mitosis, phosphor-
ylation of S4 and S8 by Cdc2 causes gel mobility shift of 
PARVA. These sites are not present in PARVB. 
PARVA phosphorylation increases during cell spreading. 
Phosphorylation during cell attachment and spreading 
appears to depend on ERK activity [35]. ERK is recruit-
ed to FAs by paxillin during cell spreading. A quintuple 
mutant of PARVA, in which all four N-terminal serines 
and T16 were mutated, was not phosphorylated and func-
tioned as dominant negative, inhibiting cell spreading 
and motility but increasing F-actin formation in human 
osteosarcoma (U2OS) cells [35]. In kidney podocytes, 
overexpression of a PARVA mutant, in which the N-
terminal proline-directed serine phosphorylation sites are 
deleted, reduced PARVA complex formation with ILK 
and inhibited podocyte adhesion, spreading and survival, 
suggesting an important role of PARVA phosphorylation 
in regulation of these processes [16]. 
The interaction of PARVA with TESK1 is also regulated 
by proline-directed serine phosphorylation of PARVA. 
Unphosphorylated PARVA binds to TESK1 and inhib-
its its activity [25], therefore allowing cofilin to reduce 
actin polymerization and spreading. Upon cell adhesion, 
ERK is activated to increase the phosphorylation at the 
N-terminus of PARVA, leading to release of TESK1, 
phosphorylation of cofilin, F-actin polymerization at the 
lamellipodia, and increased spreading and motility [25]. 
Interestingly, ILK was not pulled down by GST-TESK1 
[25], indicating that the interactions of PARVA with ILK 
and TESK1 are mutually exclusive. These results suggest 
an interesting possibility that phosphorylation of PAR-
VA, which promotes the complex formation of PARVA 
with ILK and PINCH [16], likely removes the inhibitory 
effect of PARVA on the interaction with TESK1 and 
consequently the inhibitory effect on its kinase activity. 
While the defect in cell spreading caused by mutation 
of the N-terminus of PARVA was partially corrected by 
overexpression of TESK1 lacking the PARVA binding 
site, the defect in cell spreading caused by a PBS mutant 
of PARVA deficient in paxillin binding was not [25], in-
dicating that PARVA affects cell spreading via multiple 
signaling pathways.
Regulation of Rac1 activation
The small G-proteins of the Rho family play a critical 
role in signal transduction pathways connecting integrin 
signaling and cytoskeletal dynamics [36]. In particular, 
Rac1 and Cdc42 promote cell spreading and motility, 
while RhoA promotes formation of actin stress fibers. 
Rac1 is involved in the formation of wide protrusions, 
or lamellipodia, associated with early events in cellular 
attachment and spreading, and in certain types of cel-
lular motility. In contrast, Cdc42 is more involved in the 
formation of thin protrusion, or filopodia. However, con-
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siderable overlap and cross-talking occur between these 
various Rho family members. 
Since both Rac1 and parvins regulate the formation of 
lamellipodia, it is of great interest to study the interac-
tion between integrins/PINCH/ILK/parvins and Rac1. 
Depletion of ILK and PINCH-1 significantly (50–55%) 
reduced adhesion-dependent activation of Rac1 [17]. In 
striking contrast, depletion of PARVA resulted in a sig-
nificant increase in Rac1 activity and increased spread-
ing [17]. In contrast, depletion of PARVB in Hela cells 
did not increase Rac1 activity and cell spreading [17]. 
In fact, depletion of PARVB in HeLa cells appears to 
slightly reduce Rac1 activity.
Interestingly, overexpression of the CH1 fragment of 
PARVB in MDCK cells resulted in Rac1/Cdc42 activa-
tion and increased cell spreading and motility with in-
creased formation of lamellipodia and filopodia, an effect 
blocked by dominant-negative RacN17 and Cdc42N17 
[37]. These effects appear to be mediated by interaction 
of the CH1 domain with aPIX (ARHGEF6), a GEF ac-
tivator of Cdc42 and Rac1, since an inactive mutant of 
ARHGEF6 blocked this effect of CH1. Since the interac-
tion of PARVB and aPIX appears to decrease with full-
length PARVB, two possibilities are suggested: (i) ILK 
complexes with PARVB inhibit interaction with aPIX; 
and (ii) the C-terminus of PARVB inhibits the interaction 
with aPIX. Because the CH2 domain of PARVB can be 
phosphorylated by ILK, it is possible that this induces 
a conformational change that allows the CH1 domain 
to bind to aPIX. Alpha-PIX, ILK and PARVB can be 
found at the leading edge of spreading cells [38]. It is 
likely that in some cells activation of Rac1 and Cdc42 
at the lamellipodia is stimulated by interactions of aPIX 
with PARVB and regulated by interaction of ILK and 
PARVB. In addition, PINCH, ILK and parvin proteins 
may regulate Rac activation through other GEFs such as 
DOCK180 [39]. 
Role of parvins in cell spreading and motility
The localization of both PARVA and PARVB at FAs as 
well as in the leading edge of lamellipodia suggests a role 
for these proteins in regulating cell adhesion, spreading 
and motility. Table 2 summarizes studies on the func-
tion of parvin, ILK and PINCH proteins in cell adhesion, 
spreading, motility and actin polymerization. These 
studies have demonstrated that ILK, PINCH-1, PARVA 
and PARVB complexes modulate early cellular events 
triggered by interaction with ECM, including formation 
and/or turnover of FA, actin dynamics and protrusion of 
lamellipodia to promote cellular spreading and motility. 
More specifically, ILK and PINCH-1 are required for all 
of these processes, since depletion with small interfering 
RNAs (siRNAs) significantly inhibit them. 
The role of the parvins is more complex. Based on their 
subcellular localization, PARVB appears to play an 
earlier role in lamellipodia formation. Consistent with 
an early role in cell adhesion, depletion of PARVB with 
siRNA caused inhibition of lamellipodia formation [29]. 
In contrast, depletion of PARVA actually increased cell 
spreading [22]. As we discussed above, this observation 
is consistent with the respective roles of PARVA and 
PARVB in modulating Rac1 activity, which is critical 
Table 2. Effect of ILK, PINCH and parvin proteins on cell adhesion, spreading, motility, and actin polymerization (F-actin).
Intervention Adhesion Spreading Motility F-actin Other effects Ref.
ILK siRNA delayed ⇓ ⇓  ⇓ PINCH-1 [22]
PINCH-1 siRNA  ⇓ ⇓  ⇓ ILK [22]
ILK kinase inhibitor delayed ⇓ ⇓ ⇓  [16, 18]
PARVA siRNA  ⇑   ⇓ ILK, ⇓PINCH-1 [22, 44]
PARVA 223–372 (CH2)  ⇓ ⇓ ⇓  [2, 25, 34]
PARVA PBS mutant  ⇓ ⇓ ⇓ ILK binds OK [34] 
V282G/L285R
PARVA F271D  ⇓ ⇓ ⇓  [2]
PARVA ∆N ⇓ ⇓    [16]
PARVA S4/S8/S14/T16  ⇓ ⇓ thick  [35]
/S19 to A mutant
PARVA S4D/S8D  ⇑ ⇑ fine ILK binds OK [35]
PARVB siRNA  ⇓   in some cell types [29]
PARVB 225–364 (CH2)  ⇓   reversed by active ILK [3]
PARVB 53–262 (CH1)  ⇑    [3]
PARVB 249–272, 249–262   ⇓   ⇓ a-actinin binding [29]
(a-actinin binding site)
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for lamellipodia formation, with PARVA inhibiting and 
PARVB possibly promoting Rac1 activation. In addition, 
PARVA suppresses cell spreading through inhibition of 
TESK1 activity [25]. It will be interesting to test whether 
PARVB plays an opposite role in regulation of TESK1.
As we have discussed, phosphorylation of PARVA regu-
lates its function and enhances PINCH-ILK-PARVA com-
plex formation. Interestingly, cell adhesion to fibronectin 
promotes PARVA phosphorylation, which could dis-
sociate the active TESK1 from PARVA and contribute 
to an increase of actin polymerization and cell spread-
ing. Consistent with these observations, overexpression 
of unphosphorylatable PARVA mutants (by deletion or 
mutation of N-terminal sites) acted as dominant-negative 
inhibitor of cell spreading, presumably by staying locked 
into an inactive TESK1 complex [25]. Similarly, overex-
pression of the CH2 domain of PARVA also inhibited cell 
spreading, despite proper localization to FAs. It is unclear 
whether CH1 interacting proteins, equivalent to the bind-
ing of ARHGEF6 to PARVB, also interact with PARVA 
and modulate its function at the FAs.
In platelets, an ILK-PARVB complex was rapidly recruit-
ed to integrin b3 upon thrombin stimulation, resulting in 
a transient increase in ILK activity and phosphorylation 
of PARVB followed by translocation of the ILK-PARVB 
complex to the cytoskeletal fraction, where it may pro-
mote integrin-cytoskeleton interactions [9]. In CHO 
cells, overexpression of the CH2 domain of PARVB 
blocked cell spreading. This effect was reversed by co-
transfection of ILK with intact kinase activity, suggesting 
that phosphorylation of PARVB by ILK may play a role 
in promoting cell spreading [3].
The N-terminus of PARVB CH2 domain (amino acids 
249–272) interacts with a-actinin (N-terminal ABD and 
C-terminal EF-hand domains) only upon engagement of 
integrins with the ECM, with a peak at 60 min post-adhe-
sion, when cell spreading is most active [29]. The interac-
tion with a-actinin required phosphorylation of the CH2 
domain of PARVB by ILK upon cell adhesion. Over-ex-
pression of a PARVB mutant containing only amino acids 
249–272, which can bind a-actinin but not ILK, disrupted 
the PARVB-a-actinin interaction and markedly inhibited 
lamellipodia formation and cell spreading. This effect 
was also seen with depletion of PARVB by siRNA. These 
results, together with results from other studies, suggest a 
model by which a PINCH-ILK-PARVB complex forms at 
integrin attachment sites in very early membrane blebs, 
where ILK kinase activity is induced, resulting in phos-
phorylation of the PARVB CH2 domain. PARVB then 
recruits a-actinin (or stabilizes the integrin-a-actinin 
complex) to the leading edge of the lamellipodia. PINCH, 
ILK, PARVB and a-actinin can promote lamellipodia 
extension by attracting actin polymerization complexes, 
including proteins of the Nck and ARP2/3 (through Rac/
Cdc42/WASP) families [21, 40–43].
Role of parvins on Akt activation and cell survival
PARVA plays an important role in protection of cells 
from apoptosis [44]. By contrast, depletion of PARVB 
in HeLa cells does not induce apoptosis, indicating it 
is not essential for cell survival [17]. PARVA protects 
cells from apoptosis by facilitating the activation of Akt 
(protein kinase B), a key survival signaling intermediate. 
In response to cell-matrix adhesion and soluble survival 
factors such as IGF-1, inactive Akt is translocated to 
plasma membrane, where it is phosphorylated on T308 
and S473 and consequently fully activated. Loss of 
PARVA impairs the membrane translocation of Akt 
[44]. Furthermore, expression of a constitutively mem-
brane-bound (myristoylated) Akt (Myr-Akt) rescued the 
defects in the activating phosphorylation of Akt and cell 
survival induced by the loss of PARVA. Thus, PARVA 
protects cells from apoptosis via facilitating the activat-
ing phosphorylation of Akt [44]. 
ILK depletion also affects Akt phosphorylation and acti-
vation in some cell types, particularly transformed cells 
(reviewed in [13, 45]). ILK kinase activity is transiently 
increased during cell attachment and enriched in the 
cytoskeletal fraction [18]. PARVA-depleted cells show 
much lower ILK kinase activity [18], indicating that the 
formation of the PARVA-ILK complex also plays a role 
for the activation of ILK. Mutations in ILK that abol-
ish the ILK-PARVA interaction also inhibit the ability 
of ILK to promote Akt S473 phosphorylation [18, 46]. 
In cells overexpressing PTEN, ILK kinase activity and 
PARVA interaction are inhibited. Transfection of PARVA 
restores ILK activity, as demonstrated by increased ILK 
kinase activity, GSK3b S9 phosphorylation, Akt S473 
phosphorylation and b-catenin/TCF/LEF transcriptional 
activity [18]. Although ILK and PINCH-1 likely work in 
concert with PARVA in regulation of Akt phosphoryla-
tion, Akt is not the only downstream target in ILK and 
PINCH-1-mediated cell survival signaling [22]. 
Role of parvins in striated muscle
In C. elegans, the integrin-dependent pathways involved 
in myofibrillogenesis have been clarified by forward ge-
netic screens. Deposition of the ECM protein perlecan/
UNC-52 initiates outside-in signaling transduced by 
the integrin receptor, PAT-3, which then recruits two 
complexes: (i) vinculin/DEB1, and (ii) ILK/PAT-4 + 
Mig-2/UNC-112 [5]. Both of these complexes are re-
quired for the formation of rudimentary FAs, which will 
become the initial sites of myofibril formation (the dense 
bodies) and subsequently of muscle attachment to the 
body wall. Maturation of dense bodies involves recruit-
ment of PARVA/PAT-6 and PINCH-1/UNC-97, both of 
which bind to ILK/PAT-4, as determined by yeast three-
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hybrid assay [5]. In addition to this PINCH-ILK-parvin 
complex, vinculin and talin are required for initiation of 
myofibril formation by attracting sarcomeric actin fila-
ments [5]. Alpha-actinin seems to be added to functional 
dense bodies at a later stage after larval hatching. Re-
cruitment of myosin filaments does not require vinculin; 
instead UNC-89 is required at the M-line [5]. Interest-
ingly, UNC-89 is the ortologue of an alternatively spliced 
isoform of obscurin containing several immunoglobulin 
domains and a Rho guanidine nucleotide exchange fac-
tor (GEF) domain. Obscurin and titin co-localize during 
myofibrillogenesis in cardiac myocytes [47], and the 
obscurin-RhoGEF isoform is upregulated during cardiac 
hypertrophy [48–50]. Since obscurin interacts with titin 
at the Z-line [48] and PARVA-ILK complexes are local-
ized in the costameres overlapping the Z-line of cardiac 
myocytes and play a role in myocyte hypertrophy [51], 
these observations suggest that modulation of obscurin 
activity and/or localization by ILK-PARVA complexes 
may play a role in sarcomere assembly during cardiac 
hypertrophy. In concordance with the studies in mamma-
lian cells, the CH2 domain of PARVA/PAT6 was neces-
sary and sufficient for binding to ILK and for efficient 
localization to dense bodies. The CH1 domain was dis-
pensable for proper localization, but it was required for 
downstream events leading to myofibrillogenesis. 
Recent studies have demonstrated the presence of a 
PINCH-1-ILK-PARVA complex in neonatal cardiac 
myocytes, and its recruitment to costameres associated 
with the Z-disks of newly formed sarcomeres in response 
to hypertrophic stimulation with fibronectin and phenyle-
phrine [51]. A dominant-negative mutant of ILK lacking 
PINCH-1 binding (ILK-C) removed ILK and PARVA 
from costamere locations and induced mild hypertrophy, 
while promoting apoptosis. These observations suggest 
a role for PARVA in promoting cell survival and inhibit-
ing hypertrophy in the cardiac myocyte. Since PARVA 
inhibits Rac1 activity and this small G-protein plays a 
critical role in cardiac hypertrophy [52], we are currently 
investigating the possibility that PARVA and other ILK 
complexes regulate the level of Rac1 activity in cardiac 
myocytes.
PARVB and ILK co-localized at regions of the sarco-
lemma corresponding to the Z-disk in skeletal muscle 
(costameres) [3]. In another study, PARVB co-localized 
and interacted with the sarcolemmal protein, dysferlin, in 
human skeletal muscle [53]. The sarcolemmal localiza-
tion of PARVB was reduced in muscle dystrophy with 
dysferlin mutations and may indicate a role for PARVB 
in membrane integrity. Taken together, these results 
suggest that parvin proteins may play both physical and 
signaling roles in muscle cells. 
Role of parvins in pathological processes
Given the importance of the parvins in regulating actin 
cytoskeleton and survival signaling, they are prob-
ably involved in a number of pathological processes. 
In particular, recent studies have implicated parvins in 
two human diseases, namely breast cancer and diabetic 
nephropathy.
Breast cancer
Anchorage-independent growth and resistant to apop-
tosis induced by loss of integrin-ECM contact (anoikis) 
is a hallmark of cancer cells. Moreover, changes in cell-
ECM interaction can lead to increased motility charac-
teristic of metastatic cells. Overexpression of ILK with 
hyperactive kinase function has been shown to occur in 
several transformed epithelial cells [54] and inhibition 
of ILK kinase or expression of ILK dominant-negative 
mutants can reverse several features of the transformed 
phenotype [18, 54]. The respective roles of PARVA and 
PARVB in this oncogenic role of ILK have not been 
fully characterized. PARVA has been shown to promote 
anti-apoptotic signaling from activated ILK [18, 44]. In 
contrast, in breast cancer PARVB appears to be an in-
hibitor of ILK kinase [6]. In one recent study, PARVB 
mRNA and protein levels were found to be markedly 
downregulated in a number of advanced tumors, together 
with increases in ILK protein level and kinase activity 
[6]. Low PARVB levels correlated with low adhesion to 
collagen and restoring the levels of PARVB resulted in 
increased adhesion, and reversal of anchorage-independ-
ent growth coincident with decreased ILK activity. In 
addition, overexpression of PARVB increases apoptosis 
[17]. The activating phosphorylation of Akt was reduced 
by increased levels of PARVB [6], which may translate 
in increased susceptibility of the cancer cells to apopto-
sis. Another target of ILK is GSK3b, which can regulate 
nuclear accumulation of b-catenin, frequently observed 
in transformed cells. Increased ILK activity leads to 
nuclear accumulation of b-catenin and upregulation of 
TCF/LEF targets, whereas restoring PARVB levels in 
cancer cells appears to downregulate nuclear b-catenin 
[6]. This tumor-suppressive role of PARVB is consistent 
with deletions in the PARVB locus (22q13.21) observed 
in some colon and breast cancers [55]. The PARVG gene 
was suspected to have a similar tumor suppressive role in 
a locus 12 Kb away (22q13.31), but no mutations were 
identified in colon and breast tumors [56].
Kidney disease
ILK, PARVA and PINCH-1 are expressed in glomerular 
mesangial cells and podocytes [57]. By mRNA differen-
tial display analysis, ILK was identified as a candidate 
gene in Finnish type congenital nephritic proteinuria [58]. 
ILK expression was found to be increased in glomeruli 
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[57], which could contribute to the increased matrix 
deposition in glomerulosclerosis in human patients. 
ILK is involved in mesangial cell matrix deposition in 
response to hyperglycemia [57]. In mesangial cells, the 
PINCH-1-ILK-PARVA complex locates to FAs and 
fibrillar adhesions where it promotes fibronectin matrix 
deposition [33]. Disruption of the PINCH-1-ILK-PAR-
VA complex with ILK-C or ILK-N dominant-negative 
mutants resulted in decreased cell proliferation, fibronec-
tin synthesis and matrix deposition [33].
The levels of PINCH-1, ILK and PARVA increase with 
podocyte differentiation, and the PINCH-1-ILK-PARVA 
complex plays a critical role in podocyte adhesion, archi-
tecture and survival [16]. In these cells, interference with 
the formation of the PINCH-1-ILK-PARVA complex by 
dominant-negative ILK and PARVA constructs reduced 
podocyte adhesion, spreading and survival. ILK also 
promotes upregulation of matrix metalloproteinase-9 
(MMP-9) mRNA levels and b-catenin translocation 
during podocyte stress [59–61]. In addition to its role in 
the glomerulus, ILK complexes play an important role 
in tubular cell epithelial to mesenchymal transition and 
interstitial fibrosis in response to TGF-b, tubular obstruc-
tion or hyperglycemia [62]. A dominant-negative mutant 
of ILK largely reversed these effects. 
Given the important role of the ILK-PINCH1-PARVA 
complex in renal physiology and pathology, this complex 
is a potential target for therapeutic intervention, provided 
that beneficial effects, such as podocyte adhesion and 
survival, are not significantly inhibited.
Conclusions and Future Studies
From the studies discussed in this review, it is apparent 
that PARVA and PARVB play critical roles in several cell 
functions, regulating cytoskeletal activity in connection 
with the ECM, and that these functions are mediated by 
their ability to form complexes with key proteins at the 
different subcellular locations, such as FAs, lamellipodia, 
fibrillar adhesions and possibly nuclei. In particular, the 
formation and regulation of complexes involving parvin, 
ILK and PINCH proteins as well as interactions with oth-
er ancillary proteins, such as Mig-2 [63], paxillin, ARH-
GEF6, a-actinin and TESK1, together with differential 
phosphorylation by Cdc2, ERK and ILK, mediate the 
various effects of PARVA and PARVB. Clearly, despite 
their high homology, different members of the parvin 
family have distinct functions imparted by their ability 
to form alternative complexes and differential regulation. 
Table 3 summarizes some of the features distinguishing 
the two parvins.
Despite considerable progress, much remains to be in-
vestigated to clarify the roles of parvins in cell physiol-
ogy and pathological processes. For example, PARVG 
appears similar to PARVA and PARVB, but as we have 
learned, similar domains could mediate quite different 
effects. Clarifying the role of PARVG, particularly in 
hematological cells and pathologies, will be an interest-
ing area of future research. Further investigation on the 
various PINCH-ILK-parvin complexes and their binding 
proteins in different cell types under different stimula-
tory events should help us to elucidate the role of each 
complex in cell physiology. Of particular interest is the 
elucidation of the mechanisms by which PARVA and 
PARVB regulate the activity of Rho family GTPases in 
the various cell types. Searching for additional proteins 
interacting with the CH domains, in particular the CH1 
domain of PARVA and the CH2 of PARVB, should re-
veal additional details on how parvin proteins regulate 
cell spreading, motility and survival. 
Undoubtedly, this field will continue to progress at a rap-
id pace. Further interactions and cross-talking pathways 
involving parvins and their partners will be uncovered. 
Ultimately, only a comprehensive systems biology ap-
proach well-grounded on experimental observation and 
powerful computational resources will be able to model 
and make reliable predictions about the functioning of 
this important complex network in transducing signaling 
between the ECM and the cell.
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